Founders Financial Securities LLC Lowers Holdings in Johnson & Johnson (NYSE:JNJ)

Founders Financial Securities LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 43.8% during the 1st quarter, Holdings Channel.com reports. The fund owned 13,278 shares of the company’s stock after selling 10,357 shares during the period. Founders Financial Securities LLC’s holdings in Johnson & Johnson were worth $2,100,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in JNJ. Alerus Financial NA increased its holdings in shares of Johnson & Johnson by 1.7% in the third quarter. Alerus Financial NA now owns 4,299 shares of the company’s stock worth $670,000 after purchasing an additional 71 shares during the last quarter. Elevatus Welath Management increased its holdings in shares of Johnson & Johnson by 29.1% in the third quarter. Elevatus Welath Management now owns 1,802 shares of the company’s stock worth $281,000 after purchasing an additional 406 shares during the last quarter. Legacy Advisors LLC increased its holdings in shares of Johnson & Johnson by 6.3% in the third quarter. Legacy Advisors LLC now owns 72,571 shares of the company’s stock worth $11,303,000 after purchasing an additional 4,279 shares during the last quarter. Lakeshore Financial Planning Inc. bought a new stake in shares of Johnson & Johnson in the third quarter worth about $460,000. Finally, KPP Advisory Services LLC bought a new stake in shares of Johnson & Johnson in the third quarter worth about $1,828,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.2 %

Shares of NYSE JNJ opened at $146.16 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The firm has a market capitalization of $351.76 billion, a price-to-earnings ratio of 9.11, a PEG ratio of 2.43 and a beta of 0.53. The stock has a 50 day moving average price of $148.14 and a 200 day moving average price of $154.05. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.68 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 10.62 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. Johnson & Johnson’s payout ratio is presently 30.92%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research reports. Bank of America reduced their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research note on Monday, June 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 20th. Finally, Morgan Stanley reduced their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.